Cargando…

Potential drug-drug interactions and their associated factors in hospitalized COVID-19 patients with comorbidities

BACKGROUND: Hospitalized COVID-19 patients with comorbidities receive more complex drug therapy. This increases the probability of potential drug-drug interactions (pDDIs). Studies on pDDIs in hospitalized patients with COVID-19 in countries with limited resources like Indonesia during the later per...

Descripción completa

Detalles Bibliográficos
Autores principales: Rahmadani, Imanda Dyah, Irawati, Sylvi, Wibowo, Yosi Irawati, Setiadi, Adji Prayitno
Formato: Online Artículo Texto
Lenguaje:English
Publicado: PeerJ Inc. 2023
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10314741/
https://www.ncbi.nlm.nih.gov/pubmed/37397011
http://dx.doi.org/10.7717/peerj.15072
_version_ 1785067372794609664
author Rahmadani, Imanda Dyah
Irawati, Sylvi
Wibowo, Yosi Irawati
Setiadi, Adji Prayitno
author_facet Rahmadani, Imanda Dyah
Irawati, Sylvi
Wibowo, Yosi Irawati
Setiadi, Adji Prayitno
author_sort Rahmadani, Imanda Dyah
collection PubMed
description BACKGROUND: Hospitalized COVID-19 patients with comorbidities receive more complex drug therapy. This increases the probability of potential drug-drug interactions (pDDIs). Studies on pDDIs in hospitalized patients with COVID-19 in countries with limited resources like Indonesia during the later period of the disease are still limited. This study aims to identify the pattern of pDDIs in hospitalized COVID-19 patients with comorbidities and their associated factors, especially in the second wave of the disease in Indonesia. METHODS: This study was a longitudinal-retrospective study observing hospitalized COVID-19 patients with comorbidities using medical record data in June–August 2021 at a public hospital in a region in Indonesia. pDDIs were identified using the Lexicomp(®) database. Data were descriptively analyzed. Factors associated with important pDDIs were analyzed in multivariate logistic regression model. RESULTS: A total of 258 patients with a mean age of 56.99 ± 11.94 years met the inclusion criteria. Diabetes mellitus was the most common comorbidity experienced by 58.14% of the patients. More than 70% of the patients had one comorbidity and the average number of administered drugs was 9.55 ± 2.71 items per patient. Type D pDDIs, which required modification of therapeutic regimens, amounted to 21.55% of the total interactions. Only the number of drugs was significantly and independently associated with type D pDDIs (adjusted odds ratio 1.47 [1.23–1.75], p < 0.01). CONCLUSION: The drugs involved in the pDDIs of hospitalized COVID-19 patients with comorbidities may differ depending on the disease periods, hospital settings, or countries. This study was small, single center, and of short duration. However, it may give a glimpse of important pDDIs during the delta variant of COVID-19 in a similar limited-resource setting. Further studies are needed to confirm the clinical significance of these pDDIs.
format Online
Article
Text
id pubmed-10314741
institution National Center for Biotechnology Information
language English
publishDate 2023
publisher PeerJ Inc.
record_format MEDLINE/PubMed
spelling pubmed-103147412023-07-02 Potential drug-drug interactions and their associated factors in hospitalized COVID-19 patients with comorbidities Rahmadani, Imanda Dyah Irawati, Sylvi Wibowo, Yosi Irawati Setiadi, Adji Prayitno PeerJ Drugs and Devices BACKGROUND: Hospitalized COVID-19 patients with comorbidities receive more complex drug therapy. This increases the probability of potential drug-drug interactions (pDDIs). Studies on pDDIs in hospitalized patients with COVID-19 in countries with limited resources like Indonesia during the later period of the disease are still limited. This study aims to identify the pattern of pDDIs in hospitalized COVID-19 patients with comorbidities and their associated factors, especially in the second wave of the disease in Indonesia. METHODS: This study was a longitudinal-retrospective study observing hospitalized COVID-19 patients with comorbidities using medical record data in June–August 2021 at a public hospital in a region in Indonesia. pDDIs were identified using the Lexicomp(®) database. Data were descriptively analyzed. Factors associated with important pDDIs were analyzed in multivariate logistic regression model. RESULTS: A total of 258 patients with a mean age of 56.99 ± 11.94 years met the inclusion criteria. Diabetes mellitus was the most common comorbidity experienced by 58.14% of the patients. More than 70% of the patients had one comorbidity and the average number of administered drugs was 9.55 ± 2.71 items per patient. Type D pDDIs, which required modification of therapeutic regimens, amounted to 21.55% of the total interactions. Only the number of drugs was significantly and independently associated with type D pDDIs (adjusted odds ratio 1.47 [1.23–1.75], p < 0.01). CONCLUSION: The drugs involved in the pDDIs of hospitalized COVID-19 patients with comorbidities may differ depending on the disease periods, hospital settings, or countries. This study was small, single center, and of short duration. However, it may give a glimpse of important pDDIs during the delta variant of COVID-19 in a similar limited-resource setting. Further studies are needed to confirm the clinical significance of these pDDIs. PeerJ Inc. 2023-06-28 /pmc/articles/PMC10314741/ /pubmed/37397011 http://dx.doi.org/10.7717/peerj.15072 Text en ©2023 Rahmadani et al. https://creativecommons.org/licenses/by/4.0/This is an open access article distributed under the terms of the Creative Commons Attribution License (https://creativecommons.org/licenses/by/4.0/) , which permits unrestricted use, distribution, reproduction and adaptation in any medium and for any purpose provided that it is properly attributed. For attribution, the original author(s), title, publication source (PeerJ) and either DOI or URL of the article must be cited.
spellingShingle Drugs and Devices
Rahmadani, Imanda Dyah
Irawati, Sylvi
Wibowo, Yosi Irawati
Setiadi, Adji Prayitno
Potential drug-drug interactions and their associated factors in hospitalized COVID-19 patients with comorbidities
title Potential drug-drug interactions and their associated factors in hospitalized COVID-19 patients with comorbidities
title_full Potential drug-drug interactions and their associated factors in hospitalized COVID-19 patients with comorbidities
title_fullStr Potential drug-drug interactions and their associated factors in hospitalized COVID-19 patients with comorbidities
title_full_unstemmed Potential drug-drug interactions and their associated factors in hospitalized COVID-19 patients with comorbidities
title_short Potential drug-drug interactions and their associated factors in hospitalized COVID-19 patients with comorbidities
title_sort potential drug-drug interactions and their associated factors in hospitalized covid-19 patients with comorbidities
topic Drugs and Devices
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10314741/
https://www.ncbi.nlm.nih.gov/pubmed/37397011
http://dx.doi.org/10.7717/peerj.15072
work_keys_str_mv AT rahmadaniimandadyah potentialdrugdruginteractionsandtheirassociatedfactorsinhospitalizedcovid19patientswithcomorbidities
AT irawatisylvi potentialdrugdruginteractionsandtheirassociatedfactorsinhospitalizedcovid19patientswithcomorbidities
AT wibowoyosiirawati potentialdrugdruginteractionsandtheirassociatedfactorsinhospitalizedcovid19patientswithcomorbidities
AT setiadiadjiprayitno potentialdrugdruginteractionsandtheirassociatedfactorsinhospitalizedcovid19patientswithcomorbidities